Clinical trial registry record

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 11, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06970665
Last registry update
September 11, 2026
Status
Active Not Recruiting
Phase
Phase 4
Sponsor
Astellas Pharma Inc
Enrollment
17
Countries
Japan
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
17
Population
ALL · 40 Years
Duration
2025-07-08 to 2027-06-30
Intervention
avacincaptad pegol
Comparator
Not reported
Outcomes measured
Number of participants with Treatment Emergent Adverse Events (TEAEs) — Up to 12 Months; Number of participants with Serious TEAEs — Up to 12 Months; Number of participants with intraocular pressure (IOP) abnormalities and/or AEs — Up to 12 months; Number of participants with ophthalmic examination abnormalities and/or AEs — Up to 12 months; Number of participants with laboratory value abnormalities and/or AEs — Up to 12 months; Number of participants with vital signs abnormalities and/or AEs — Up to 12 months; Number of participants with 12-lead electrocardiogram (ECG) abnormalities and/or AEs — Up to 12 months; Mean rate of growth (slope) over 12 months — Up to 12 months; Change from baseline in best corrected visual acuity (BCVA) — Baseline and up to 12 months; Change from baseline in low luminance best corrected visual acuity (LL BCVA) — Baseline and up to 12 months; Number of participants with antidrug antibodies (ADA) status — Up to 12 months; Number of participants with neutralizing antibodies (NAb) status for participant with positive ADA — Up to 12 months; PK of ASP3021 in plasma: Concentration — Up to 2 months; Pharmacokinetics (PK) of ASP3021 in plasma: concentration immediately prior to dosing at multiple dosing (Ctrough) — Up…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON